Validation and reliability of the Neuropathic Pain Scale (NPS) in multiple sclerosis

Clinical Journal of Pain

Volumn 23, Issue 6, 2007, Pages 473-481

  Rog, David J ^a   Nurmikko, Turo J ^b   Friede, Tim ^c   Young, Carolyn A ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b Pain Research Institute   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Central pain; Multiple sclerosis; Neuropathic pain; Neuropathic Pain Scale; Validation

Indexed keywords

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; CRONBACH ALPHA COEFFICIENT; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MCGILL PAIN QUESTIONNAIRE; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NEUROPATHIC PAIN SCALE; PAIN ASSESSMENT; PRIORITY JOURNAL; RELIABILITY; SHORT FORM 36; VISUAL ANALOG SCALE;

ADULT; AGED; DATA INTERPRETATION, STATISTICAL; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PAIN; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; REPRODUCIBILITY OF RESULTS; SPASM; TRIGEMINAL NEURALGIA;

EID: 34250765703     PISSN: 07498047     EISSN: None     Source Type: Journal    
DOI: 10.1097/AJP.0b013e31805d0c5d     Document Type: Article

References (59)

1. Charcot JM. LeCons Sur le Maladies du Systeme Nerveux Faites a la Salpetriere. Paris: Delahaye; 1872:239-240.
2. Clifford DB, Trotter JL. Pain in multiple sclerosis. Arch Neurol. 1984;41:1270-1272.
3. Vermote R, Ketelaer P, Carton H. Pain in multiple sclerosis patients. Clin Neurol Neurosurg. 1986;88:87-93.
4. Kassirer MR, Osterberg DH. Pain in multiple sclerosis. Am J Nurs. 1987;7:968-969.
5. Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology. 1988;38:1830-1834.
6. Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand. 1991;84:197-200.
7. Osterberg A, Boivie J, Thuomas A. Central pain in multiple sclerosis - prevalence and clinical characteristics. Eur J Pain. 2005;9:531-542.
8. Archibald CJ, McGrath PJ, Ritvo PG, et al. Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain. 1994;58:89-93.
9. Svendsen KB, Jensen TS, Overvad K, et al. Pain in patients with multiple sclerosis. A population-based survey. Arch Neurol. 2003;60:1089-1094.
10. Shibasaki H, Kuroiwa Y. Painful tonic seizures in multiple sclerosis. Arch Neurol. 1974;30:47-51.
11. Albert ML. Treatment of pain in multiple sclerosis-preliminary report. N Engl J Med. 1969;280:1395.
12. Thompson AJ. Symptomatic treatment in multiple sclerosis. Curr Opin Neurol. 1998;11:305-309.
13. Gonzales GR, Casey KL. Central pain syndromes. In: Jensen TS, Wilson PR, Rice ASC, editors. Clinical Pain Management: Chronic Pain. London: Arnold; 2003:403-416.
14. Hansson P. Difficulties in stratifying neuropathic pain by mechanisms. Eur J Pain. 2003;7:353-357.
15. Attal N, Bouhassira D. Can pain be more or less neuropathic? Pain. 2004;110:510-511.
16. Max MB. Neuropathic pain syndromes. In: Max M, Portenoy R, Laska E, editors. Advances in Research and Therapy. Vol 18. New York: Raven Press Ltd; 1991:193-219.
17. Krause SJ, Backonja M-M. Development of a Neuropathic Pain Questionnaire. Clin J Pain. 2003;19:306-314.
18. Bennett M. The LANSS scale: the Leeds Assessment of Neuropathic Symptoms and Signs. Pain. 2001;92:147-157.
19. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108:248-257.
20. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48:332-338.
21. Galer BS, Jensen MP, Ma T, et al. The lidocaine patch 5% effectively treats neuropathic pain: results of a randomized double blind, vehicle-controlled, 3-week efficacy study with use of the Neuropathic Pain Scale. Clin J Pain. 2002;18:297-301.
22. Galer BS, Miller KV, Rowbotham MC. Response to intravenous lidocaine infusion differs based on clinical diagnosis and site of nervous system injury. Neurology. 1993;43:1233-1235.
23. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
24. Spissu A, Cannas A, Ferrigno P, et al. Anatomic correlates of painful tonic spasms in multiple sclerosis. Mov Disord. 1999;14:331-335.
25. Gass A, Kitchen N, MacManus DG, et al. Trigeminal neuralgia in patients with multiple sclerosis: lesion localization with magnetic resonance imaging. Neurology. 1997;49:1142-144.
26. Moulin DE. Pain in multiple sclerosis. Neurology Clinics. 1989;7:321-331.
27. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191-197.
28. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361-370.
29. Ware JE Jr, Snow KK, Konsinski M, et al. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Centre; 1993.
30. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA. 1998;280:1831-1836.
31. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia. JAMA. 1998;280:1837-1842.
32. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability scale. Neurology. 1983;33:1444-1452.
33. Cronbach LJ. Coefficent alpha and the internal structure of tests. Psychometrika. 1951;16:297-334.
34. Davison AC, Hinkley DV. Bootstrap Methods and their Applications. Cambridge University Press; 1997.
35. Lyons RA, Wareham K, Lucas M, et al. SF-36 scores vary by method of administration: implications for study design. J Public Health Med. 1999;21:41-45.
36. Bland M, Altman D. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8:135-160.
37. Bland M, Altman D. Measurement error and correlation coefficients. BMJ. 1996;313:41-42.
38. Rao PSRS. Variance Components Estimation: Mixed Models, Methodologies and Applications. London: Chapman & Hall; 1997.
39. Afifi AA, Clark VA. Computer-aided Multivariate Analysis. (Chapman & Hall Texts in Statistical Science). 3rd ed. London: Chapman & Hall; 1996.
40. Helmstadter GC. Principles of Psychological Measurement. New York: Apple Century-Crofts; 1964.
41. Nuneally JC. Psychometric Theory. 2nd ed. New York: McGraw Hill; 1978.
42. Bland JM, Altman DG. Cronbach's alpha. BMJ. 1997;314:572.
43. Holmes W, Shea J. Performance of a new HIV/AIDS-targeted quality of life (HAT-QoL) instrument in asymptomatic seropositive individuals. Qual Life Res. 1997;6:561-571.
44. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:253-258.
45. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812-819.
46. Galer BS, Twilling LL, Harle J, et al. Lack of efficacy of riluzole in the treatment of peripheral neuropathic pain conditions. Neurology. 2000;55:971-975.
47. Negri E, Bettaglio R, Demartini L, et al. Validation of the Italian version of the Neuropathic Pain Scale and its clinical applications. Minerva Anestesiol. 2002;68:95-104.
48. Biovie J. Central pain. In: Wall PD, Melzack R, eds. Textbook of Pain. 4th ed. Hong Kong: Harcourt; 1999:879-914.
49. Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain. 2003;102:1-8.
50. Hobart JC, Lamping DL, Thompson AJ. Evaluating neurological outcome measures: the bare essentials. J Neurol Neurosurg Psychiatry. 1996;60:127-130.
51. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol. 1997;50:1129-1136.
52. Eisendrath SJ. Psychiatric aspects of chronic pain. Neurology. 1995;45:S26-S34.
53. Indaco A, Iachetta C, Nappi C, et al. Chronic and acute pain syndromes in patients with multiple sclerosis. Acta Neurologica (Napoli). 1994;16:97-102.
54. Freeman JA, Hobart JC, Thompson AJ. Does adding MS-specific items to a generic measure (the SF-36) improve measurement? Neurology. 2001;57:68-74.
55. Selai CE, Trimble MR. Patients' assessment of disability in Multiple Sclerosis. BMJ. 1997;315:1305-1306.
56. Boivie J. Central Pain. In: Merskey H, Loeser JD, Dubner R, eds. The Paths of Pain 1975-2005. Seattle: IASP Press; 2005: 299-312.
57. Attal N. Chronic neuropathic pain: mechanisms and treatment. Clin J Pain. 2000;26:S118-S130.
58. Cleeland CS. Issues in pain management. In: Chapman CR, Loeser JD, eds. Advances in Pain Research and Therapy. Vol 12. New York: Raven Press; 1989.
59. Osterberg A, Boivie J, Holmgren H, et al. The clinical characteristics and sensory abnormalities of patients with central pain caused by multiple sclerosis. In: Gebhart GF, Hammond DL, Jensen TS, eds. Proc 7th World Congress on Pain, Prog in Pain Research and Management. Seattle: IASP Press; 1994:789-796.